Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24410169 | 0.75 | MAPT (0.44) | KDM4EALDH1A1MAPTBLMPOLB | |
| SCHEMBL16826030 | 0.74 | KDM4E (0.42) | IDO1KDM4EALDH1A1MAPTBLM | |
| SCHEMBL23982542 | 0.70 | RAB9A (0.57) | KDM4EALDH1A1MAPTBLMPOLB | |
| SCHEMBL16826014 | 0.70 | MKNK1 (0.39) | IDO1KDM4EALDH1A1MAPTBLM | |
| SCHEMBL10718532 | 0.69 | SCN2A (0.37) | IDO1KDM4EALDH1A1PLAUPOLB | |
| SCHEMBL474171 | 0.67 | NOTUM (0.61) | KDM4EALDH1A1MAPTBLMPOLB | |
| SCHEMBL16847996 | 0.67 | MAPT (0.46) | KDM4EALDH1A1MAPTBLMPOLB | |
| SCHEMBL16826415 | 0.64 | KMO (0.50) | KDM4EALDH1A1MAPTBLMPOLB | |
| SCHEMBL3933042 | 0.64 | MAPT (0.50) | IDO1KDM4EALDH1A1MAPTBLM | |
| SCHEMBL120637 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265085-A1 | RET KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265085-A1 | RET KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11697647-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697647-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2022098970-A9 | PYRAZOLE DERIVATIVES AS RET KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022098970-A1 | PYRAZOLE DERIVATIVES ASR ET KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220144816-A1 | RET KINASE INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697647-B2 | RET kinase inhibitors | RET, BRAF, GFRA1 | IDO1 4605/4885KDM4E 1642/4885ALDH1A1 1205/4885 |
| US-20230265085-A1 | RET KINASE INHIBITORS | RET, BRAF, GFRA1 | IDO1 4605/4885KDM4E 1642/4885ALDH1A1 1205/4885 |
| US-20220144816-A1 | RET KINASE INHIBITORS | RET, BRAF, GFRA1 | IDO1 4605/4885KDM4E 1642/4885ALDH1A1 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.